BRPI1012560A2 - anticorpos anti-fcrh5 e imunoconjugados e métodos de uso - Google Patents
anticorpos anti-fcrh5 e imunoconjugados e métodos de usoInfo
- Publication number
- BRPI1012560A2 BRPI1012560A2 BRPI1012560A BRPI1012560A BRPI1012560A2 BR PI1012560 A2 BRPI1012560 A2 BR PI1012560A2 BR PI1012560 A BRPI1012560 A BR PI1012560A BR PI1012560 A BRPI1012560 A BR PI1012560A BR PI1012560 A2 BRPI1012560 A2 BR PI1012560A2
- Authority
- BR
- Brazil
- Prior art keywords
- fcrh5
- methods
- immunoconjugate antibodies
- immunoconjugate
- antibodies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21175409P | 2009-04-01 | 2009-04-01 | |
| US16621409P | 2009-04-02 | 2009-04-02 | |
| PCT/US2010/029521 WO2010114940A1 (en) | 2009-04-01 | 2010-03-31 | Anti-fcrh5 antibodies and immunoconjugates and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1012560A2 true BRPI1012560A2 (pt) | 2016-07-26 |
Family
ID=42236394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1012560A BRPI1012560A2 (pt) | 2009-04-01 | 2010-03-31 | anticorpos anti-fcrh5 e imunoconjugados e métodos de uso |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US8362213B2 (enExample) |
| EP (1) | EP2414395A1 (enExample) |
| JP (2) | JP6099976B2 (enExample) |
| KR (1) | KR20120003478A (enExample) |
| CN (1) | CN102369218B (enExample) |
| AR (1) | AR076030A1 (enExample) |
| AU (1) | AU2010232682A1 (enExample) |
| BR (1) | BRPI1012560A2 (enExample) |
| CA (1) | CA2756988A1 (enExample) |
| CL (1) | CL2011002418A1 (enExample) |
| IL (1) | IL215404A0 (enExample) |
| MX (1) | MX2011010265A (enExample) |
| PE (1) | PE20120877A1 (enExample) |
| RU (2) | RU2583270C2 (enExample) |
| SG (1) | SG174930A1 (enExample) |
| TW (1) | TW201039846A (enExample) |
| WO (1) | WO2010114940A1 (enExample) |
| ZA (1) | ZA201107128B (enExample) |
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20120877A1 (es) | 2009-04-01 | 2012-08-06 | Genentech Inc | ANTICUERPOS ANTI-FcRH5 E INMUNOCONJUGADOS |
| MA33256B1 (fr) | 2009-04-01 | 2012-05-02 | Genentech Inc | Anticorps et immunoconjugués anti-fcrh5 et procédés d'utilisation |
| US8962804B2 (en) | 2010-10-08 | 2015-02-24 | City Of Hope | Meditopes and meditope-binding antibodies and uses thereof |
| KR20200128601A (ko) | 2011-05-27 | 2020-11-13 | 암브룩스, 인코포레이티드 | 비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도 |
| US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| EP2717916B1 (en) | 2011-06-10 | 2017-03-08 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| US9428553B2 (en) | 2012-02-10 | 2016-08-30 | City Of Hope | Meditopes and meditope-binding antibodies and uses thereof |
| EA201591465A1 (ru) * | 2013-02-08 | 2015-12-30 | АйАрЭм ЭлЭлСи | Специфичные участки для модификации антител для получения иммуноконъюгатов |
| JP6671956B2 (ja) * | 2013-03-29 | 2020-03-25 | 大日本住友製薬株式会社 | Ｅｒａｐ１によるトリミング機能をきっかけとしたコンジュゲートワクチン |
| WO2014157692A1 (ja) | 2013-03-29 | 2014-10-02 | 大日本住友製薬株式会社 | Ｗｔ１抗原ペプチドコンジュゲートワクチン |
| TWI725931B (zh) * | 2013-06-24 | 2021-05-01 | 美商建南德克公司 | 抗ｆｃｒｈ５抗體 |
| CN110251683A (zh) * | 2013-06-24 | 2019-09-20 | Abl生物公司 | 具有改进的稳定性的抗体-药物缀合物及其用途 |
| WO2015054659A1 (en) | 2013-10-11 | 2015-04-16 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| CA2927022C (en) | 2013-10-11 | 2018-08-21 | Asana Biosciences, Llc | Protein-polymer-drug conjugates |
| HUE050159T2 (hu) * | 2013-12-17 | 2020-11-30 | Genentech Inc | Anti-CD3 antitestek és alkalmazási eljárások |
| MA40579A (fr) | 2014-09-12 | 2016-03-17 | Genentech Inc | Anticorps anti-cll-1 et immunoconjugués |
| CA2966005C (en) | 2014-10-31 | 2021-04-27 | Abbvie Biotherapeutics Inc. | Anti-cs1 antibodies and antibody drug conjugates |
| WO2016090337A1 (en) | 2014-12-05 | 2016-06-09 | Memorial Sloan-Kettering Cancer Center | Chimeric antigen receptors targeting fc receptor-like 5 and uses thereof |
| US10017577B2 (en) * | 2015-06-15 | 2018-07-10 | Genentech, Inc. | Antibodies and immunoconjugates |
| US10323094B2 (en) * | 2015-06-16 | 2019-06-18 | Genentech, Inc. | Humanized and affinity matured antibodies to FcRH5 and methods of use |
| EP3310811B1 (en) | 2015-06-16 | 2021-06-16 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
| TW201718647A (zh) | 2015-06-16 | 2017-06-01 | 建南德克公司 | 抗-cll-1抗體及使用方法 |
| PH12018501177B1 (en) * | 2015-12-04 | 2024-01-24 | Eureka Therapeutics Inc | Antibodies targeting fc receptor-like 5 and methods of use |
| WO2017188346A1 (ja) * | 2016-04-27 | 2017-11-02 | 国立大学法人 東京大学 | マイクロファイバーを用いた血中循環細胞の捕捉及び回収用材料及び当該材料を用いる方法 |
| CN109641051A (zh) * | 2016-06-17 | 2019-04-16 | 美真达治疗公司 | 用于耗尽细胞的组合物和方法 |
| EP3541843A1 (en) | 2016-11-15 | 2019-09-25 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies |
| WO2018101309A1 (ja) | 2016-11-30 | 2018-06-07 | 大日本住友製薬株式会社 | Ｗｔ１ヘルパーペプチド及びこれと癌抗原ペプチドコンジュゲート体との組合せ |
| TWI804499B (zh) * | 2017-06-23 | 2023-06-11 | 美商維洛斯生物公司 | Ror1抗體免疫接合物 |
| KR20200036889A (ko) | 2017-07-28 | 2020-04-07 | 에프. 호프만-라 로슈 아게 | 이중특이성 항체 제형 |
| CN111051329B (zh) * | 2017-08-10 | 2024-07-30 | 住友制药株式会社 | 哈米特林衍生物及它们的抗体药物复合物 |
| CA3072153A1 (en) * | 2017-08-10 | 2019-02-14 | Sumitomo Dainippon Pharma Co., Ltd. | Antibody-drug conjugates including hemiasterlin derivative |
| US10766613B2 (en) * | 2017-11-28 | 2020-09-08 | Textron Innovations Inc. | System and method for rotorcraft-weight-on-wheels flight state transition control |
| US12247060B2 (en) | 2018-01-09 | 2025-03-11 | Marengo Therapeutics, Inc. | Calreticulin binding constructs and engineered T cells for the treatment of diseases |
| CR20200391A (es) | 2018-02-08 | 2020-10-19 | Genentech Inc | Moléculas biespecíficas de unión al antígeno y métodos de uso |
| CN120005029A (zh) | 2018-03-06 | 2025-05-16 | 英凯尔生物科技有限责任公司 | 丝氨酸蛋白酶抑制剂Kazal(SPIK)组合物和方法 |
| EP3765517A1 (en) | 2018-03-14 | 2021-01-20 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| WO2019237035A1 (en) | 2018-06-08 | 2019-12-12 | Intellia Therapeutics, Inc. | Compositions and methods for immunooncology |
| WO2020010250A2 (en) | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| EP3826678A4 (en) * | 2018-07-25 | 2022-06-15 | Northeastern University | SELECTIVITY SCREENING FOR ANTIMICROBIAL COMPOUNDS |
| IT201800009282A1 (it) * | 2018-10-09 | 2020-04-09 | Metis Prec Medicine Sb Srl | Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi |
| AU2019402189B2 (en) | 2018-12-20 | 2023-04-13 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| JP7560255B2 (ja) * | 2019-02-13 | 2024-10-02 | 住友ファーマ株式会社 | ヘミアスタリン誘導体を含む抗体薬物複合体を含有する医薬 |
| US12178879B2 (en) | 2019-02-13 | 2024-12-31 | Sumitomo Pharma Co., Ltd. | Hemiasterlin derivative and antibody-drug conjugate thereof |
| CN113412271B (zh) | 2019-02-13 | 2024-10-22 | 住友制药株式会社 | 具有半胱氨酸残基的哈米特林衍生物 |
| CA3123519A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| EP3924054B1 (en) | 2019-02-15 | 2025-04-02 | Novartis AG | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| JP7579795B2 (ja) | 2019-02-21 | 2024-11-08 | マレンゴ・セラピューティクス，インコーポレーテッド | ＮＫｐ３０に結合する抗体分子およびその使用 |
| AU2020226893B2 (en) | 2019-02-21 | 2025-02-27 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
| CN111909268B (zh) * | 2019-05-07 | 2022-04-19 | 北京天成新脉生物技术有限公司 | 低免疫原性低ADCC/CDC功能抗TNF-α人源化单克隆抗体TCX060及其应用 |
| JP7658946B2 (ja) * | 2019-07-08 | 2025-04-08 | インケア バイオテック， エルエルシー | カザール型抗セリンプロテアーゼ阻害因子（ｓｐｉｋ）抗体、免疫複合体、及び使用方法 |
| KR20220080098A (ko) | 2019-09-11 | 2022-06-14 | 아임케어 바이오테크, 엘엘씨. | 항-세린 프로테아제 억제제 카잘(spik) 항체의 에피토프 |
| CR20220330A (es) | 2019-12-13 | 2022-08-04 | Genentech Inc | Anticuerpos anti-ly6g6d y métodos de uso. |
| BR112022011824A2 (pt) | 2019-12-18 | 2022-08-30 | Teneofour Inc | Anticorpos de cadeia pesada que se ligam a cd38 |
| US20230057071A1 (en) | 2019-12-20 | 2023-02-23 | Novartis Ag | Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome |
| WO2021138474A2 (en) | 2020-01-03 | 2021-07-08 | Marengo Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| EP4168007A1 (en) | 2020-06-23 | 2023-04-26 | Novartis AG | Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| EP4188549A1 (en) | 2020-08-03 | 2023-06-07 | Novartis AG | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| EP4225792A1 (en) | 2020-10-08 | 2023-08-16 | Affimed GmbH | Trispecific binders |
| JP7716473B2 (ja) | 2020-11-04 | 2025-07-31 | ジェネンテック， インコーポレイテッド | 抗ｃｄ２０／抗ｃｄ３二重特異性抗体の皮下投薬 |
| WO2022098638A2 (en) | 2020-11-04 | 2022-05-12 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies |
| EP4240493A2 (en) | 2020-11-04 | 2023-09-13 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates |
| CN114621354A (zh) * | 2020-12-11 | 2022-06-14 | 正大天晴药业集团股份有限公司 | Fab-白蛋白结合肽融合蛋白及其制备方法和应用 |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| CA3214757A1 (en) | 2021-04-08 | 2022-10-13 | Andreas Loew | Multifuntional molecules binding to tcr and uses thereof |
| AR125468A1 (es) | 2021-04-27 | 2023-07-19 | Novartis Ag | Sistema de producción de vectores virales |
| CA3213632A1 (en) | 2021-04-30 | 2022-11-03 | F. Hoffmann-La Roche Ag | Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate |
| KR20240007171A (ko) | 2021-05-14 | 2024-01-16 | 제넨테크, 인크. | 모수네투주맙 및 폴라투주맙 베도틴을 이용한 cd20 양성 증식성 장애의 치료 방법 |
| US12686715B2 (en) | 2021-06-01 | 2026-07-21 | Genentech, Inc. | Methods for treatment of B cell proliferative disorders with anti-CD20/anti-CD3 bispecific antibodies |
| GB202116502D0 (en) * | 2021-11-16 | 2021-12-29 | Autolus Ltd | Binding doman |
| WO2022271987A1 (en) | 2021-06-23 | 2022-12-29 | TeneoFour, Inc. | Anti-cd38 antibodies and epitopes of same |
| JP2024529381A (ja) | 2021-07-30 | 2024-08-06 | アフィメド ゲーエムベーハー | デュプレックスボディ |
| TW202334221A (zh) | 2021-11-03 | 2023-09-01 | 德商安富美德有限公司 | 雙特異性cd16a結合劑 |
| AU2023254206A1 (en) | 2022-04-13 | 2024-10-17 | Genentech, Inc. | Pharmaceutical compositions of mosunetuzumab and methods of use |
| TW202545564A (zh) * | 2022-04-13 | 2025-12-01 | 美商建南德克公司 | 治療性蛋白質之醫藥組成物及使用方法 |
| WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
| JP2026519263A (ja) | 2022-10-26 | 2026-06-15 | ノバルティス アーゲー | レンチウイルス製剤 |
| WO2024102954A1 (en) | 2022-11-10 | 2024-05-16 | Massachusetts Institute Of Technology | Activation induced clipping system (aics) |
| WO2024102948A1 (en) * | 2022-11-11 | 2024-05-16 | Celgene Corporation | Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods |
| CN116199772B (zh) * | 2022-11-16 | 2023-10-17 | 怡道生物科技(苏州)有限公司 | Hpv31型衣壳蛋白l1单克隆抗体、制备方法及应用 |
| TW202544034A (zh) | 2024-05-06 | 2025-11-16 | 美商榮都醫療公司 | 結合至ｃｄ２８及ｎｅｃｔｉｎ－４之雙特異性抗體 |
| WO2026050572A2 (en) | 2024-08-29 | 2026-03-05 | Marengo Therapeutics, Inc. | Multifunctional molecules binding to tcr and uses thereof |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| EP0731106B1 (en) | 1993-10-01 | 2004-11-17 | Teikoku Hormone Mfg. Co., Ltd. | Dolastatin derivatives |
| US20020132252A1 (en) | 1997-06-16 | 2002-09-19 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US6248564B1 (en) | 1997-08-29 | 2001-06-19 | Harvard University | Mutant MHC class I molecules |
| US7105149B1 (en) | 1999-11-29 | 2006-09-12 | The Trustees Of Columbia University In The City Of New York | Isolation of five novel genes coding for new Fc receptors-type melanoma involved in the pathogenesis of lymphoma/myeloma |
| ES2586850T3 (es) * | 1999-11-29 | 2016-10-19 | The Trustees Of Columbia University In The City Of New York | Aislamiento de cinco genes novedosos que codifican nuevos melanomas de tipo receptor de Fc implicados en la patogénesis del linfoma/melanoma |
| US20040005561A1 (en) | 2000-03-01 | 2004-01-08 | Corixa Corporation | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
| US20040018194A1 (en) | 2000-11-28 | 2004-01-29 | Francisco Joseph A. | Recombinant anti-CD30 antibodies and uses thereof |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| IL159177A0 (en) * | 2001-06-20 | 2004-06-01 | Prochon Biotech Ltd | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| NZ573739A (en) | 2001-09-18 | 2010-07-30 | Genentech Inc | Compositions and methods for the diagnosis and treatment of tumor, particularly colorectal tumor - TAT201 |
| US7888478B2 (en) | 2002-09-11 | 2011-02-15 | Genentech, Inc. | Compositions and methods for the treatment of tumor of hematopoietic origin |
| US7858330B2 (en) | 2001-10-19 | 2010-12-28 | Genentech, Inc. | Compositions and methods for the treatment of tumor of hematopoietic origin |
| US20050123536A1 (en) | 2001-11-20 | 2005-06-09 | Che-Leung Law | Treatment of immunological disorders using anti-dc30 antibodies |
| CA2494104A1 (en) | 2002-07-31 | 2004-04-22 | Seattle Genetics, Inc. | Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders |
| EP1391213A1 (en) | 2002-08-21 | 2004-02-25 | Boehringer Ingelheim International GmbH | Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents |
| ES2605443T3 (es) | 2003-11-06 | 2017-03-14 | Seattle Genetics, Inc. | Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia |
| JP4658967B2 (ja) | 2003-12-24 | 2011-03-23 | ジェネンテック， インコーポレイテッド | 造血系起源の腫瘍の治療のための組成物と方法 |
| NZ551180A (en) * | 2004-06-01 | 2009-10-30 | Genentech Inc | Antibody drug conjugates and methods |
| TR201808537T4 (tr) * | 2004-09-23 | 2018-07-23 | Genentech Inc | Sistein değiştirilmiş antikorlar ve konjugatlar. |
| US7999077B2 (en) | 2004-09-30 | 2011-08-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | IRTA2 antibodies and methods of use |
| US7947839B2 (en) | 2004-12-01 | 2011-05-24 | Genentech, Inc. | Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use |
| US20070134243A1 (en) | 2004-12-01 | 2007-06-14 | Gazzard Lewis J | Antibody drug conjugates and methods |
| EP1846449A4 (en) * | 2005-01-12 | 2009-07-08 | Medarex Inc | IRTA-2 ANTIBODIES AND THEIR USE |
| US7989595B2 (en) * | 2005-06-20 | 2011-08-02 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| WO2008109533A2 (en) * | 2007-03-02 | 2008-09-12 | Medarex, Inc. | Human antibodies that bind multiple irta family proteins, and uses thereof |
| PE20120877A1 (es) | 2009-04-01 | 2012-08-06 | Genentech Inc | ANTICUERPOS ANTI-FcRH5 E INMUNOCONJUGADOS |
| MA33256B1 (fr) | 2009-04-01 | 2012-05-02 | Genentech Inc | Anticorps et immunoconjugués anti-fcrh5 et procédés d'utilisation |
-
2010
- 2010-03-31 PE PE2011001751A patent/PE20120877A1/es not_active Application Discontinuation
- 2010-03-31 AR ARP100101080A patent/AR076030A1/es not_active Application Discontinuation
- 2010-03-31 AU AU2010232682A patent/AU2010232682A1/en not_active Abandoned
- 2010-03-31 BR BRPI1012560A patent/BRPI1012560A2/pt not_active IP Right Cessation
- 2010-03-31 WO PCT/US2010/029521 patent/WO2010114940A1/en not_active Ceased
- 2010-03-31 TW TW099109950A patent/TW201039846A/zh unknown
- 2010-03-31 KR KR1020117025849A patent/KR20120003478A/ko not_active Abandoned
- 2010-03-31 EP EP10711526A patent/EP2414395A1/en not_active Ceased
- 2010-03-31 JP JP2012503682A patent/JP6099976B2/ja not_active Expired - Fee Related
- 2010-03-31 SG SG2011069895A patent/SG174930A1/en unknown
- 2010-03-31 RU RU2011144119/10A patent/RU2583270C2/ru not_active IP Right Cessation
- 2010-03-31 RU RU2016110891A patent/RU2016110891A/ru not_active Application Discontinuation
- 2010-03-31 US US12/751,791 patent/US8362213B2/en not_active Expired - Fee Related
- 2010-03-31 MX MX2011010265A patent/MX2011010265A/es active IP Right Grant
- 2010-03-31 CA CA2756988A patent/CA2756988A1/en not_active Abandoned
- 2010-03-31 CN CN201080014347.1A patent/CN102369218B/zh not_active Expired - Fee Related
-
2011
- 2011-09-27 IL IL215404A patent/IL215404A0/en unknown
- 2011-09-29 ZA ZA2011/07128A patent/ZA201107128B/en unknown
- 2011-09-30 CL CL2011002418A patent/CL2011002418A1/es unknown
-
2012
- 2012-11-09 US US13/673,565 patent/US9017951B2/en not_active Expired - Fee Related
-
2015
- 2015-08-27 JP JP2015168182A patent/JP2016028052A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| HK1166805A1 (en) | 2012-11-09 |
| MX2011010265A (es) | 2011-10-11 |
| RU2016110891A (ru) | 2018-11-27 |
| US20130089497A1 (en) | 2013-04-11 |
| JP2016028052A (ja) | 2016-02-25 |
| JP6099976B2 (ja) | 2017-03-29 |
| PE20120877A1 (es) | 2012-08-06 |
| JP2012522513A (ja) | 2012-09-27 |
| CL2011002418A1 (es) | 2012-03-16 |
| WO2010114940A1 (en) | 2010-10-07 |
| US20110171125A1 (en) | 2011-07-14 |
| IL215404A0 (en) | 2011-12-29 |
| AU2010232682A1 (en) | 2011-11-10 |
| CA2756988A1 (en) | 2010-10-07 |
| US8362213B2 (en) | 2013-01-29 |
| AR076030A1 (es) | 2011-05-11 |
| EP2414395A1 (en) | 2012-02-08 |
| US9017951B2 (en) | 2015-04-28 |
| TW201039846A (en) | 2010-11-16 |
| SG174930A1 (en) | 2011-11-28 |
| CN102369218A (zh) | 2012-03-07 |
| KR20120003478A (ko) | 2012-01-10 |
| ZA201107128B (en) | 2012-12-27 |
| CN102369218B (zh) | 2014-07-16 |
| RU2583270C2 (ru) | 2016-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1012676A2 (pt) | anticorpos anti-fcrh5 e imunoconjugados e métodos de uso | |
| PT2247620T (pt) | Anticorpos e imunoconjugados anti-cd79b e métodos de utilização | |
| PT2474557E (pt) | Anticorpos e imunoconjugados anti-cd79b e métodos de utilização | |
| BRPI1014544A8 (pt) | anticorpos anti-il-17f e metodos de uso dos mesmos | |
| PL2990421T3 (pl) | Przeciwciała anty-ceacam1 oraz sposoby ich stosowania | |
| BRPI0813514A2 (pt) | anticorpos anti-cd79b humanizados e imunoconjugados e métodos de uso | |
| BR112014028366A2 (pt) | anticorpos anti-ly6e e imunoconjugados e métodos de uso | |
| PL2427212T3 (pl) | Przeciwciała anty cd-100 i sposoby ich zastosowania | |
| BRPI1011384A2 (pt) | pro-proteinas e seus metodos de uso | |
| BR112012018329A2 (pt) | agentes de coloração e métodos de uso destes | |
| BRPI1012333A2 (pt) | atropisômeros de derivados de 2-purinil-3-tolil-quinazolinonas e métodos de uso | |
| PL2488551T3 (pl) | Przeciwciała monoklonalne przeciwko progastrynie i ich zastosowania | |
| BRPI1007175A2 (pt) | Polipeptídeos hidroxifenilpriruvato dioxigenase mutantes e métodos de uso | |
| IL215404A0 (en) | Anti-fcrh5 antibodies and immunoconjugates and methods of use | |
| PL2644194T3 (pl) | Kombinacje koniugatu przeciwciała anty-HER2-lek i docetakselu | |
| BRPI0915928A2 (pt) | composições e métodos de uso para anticorpos terapêuticos | |
| BRPI0821110A2 (pt) | Anticorpo anti nr-10 e uso do mesmo | |
| BRPI0922708A2 (pt) | peptídeos mini-hepcidina e métodos de uso do mesmo | |
| BRPI0906478A2 (pt) | anticorpo anti-nr10 e uso do mesmo | |
| BR112013014321A2 (pt) | moduladores inovadores e métodos de uso | |
| BR112014002716A2 (pt) | anticorpos anti-poliubiquitina e métodos de uso | |
| CO7020870A2 (es) | Anticuerpos anti-htra1 y métodos de uso | |
| BRPI1005670A2 (pt) | composições adjuvantes e métodos de uso | |
| BRPI0820407A2 (pt) | Uso de anticorpos anti-cd40 | |
| CR20130133A (es) | Composiciones de anticuerpo y mètodos de uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A ANUIDADE. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2508 DE 29-01-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |